| B-raf V599E and V599K oncogenic mutations are likely to affect melanocyte-specific pathways controlling proliferation and differentiation | None |
| Mutational analysis of the BRAF gene in human congenital and dysplastic melanocytic naevi. | None |
| The oncogenic B-raf mutations V599E and V599K, as early events in melanocyte transformation, persist throughout metastasis with important prognostic implications. | None |
| Quail neuroretina c-Rmil(B-raf) proto-oncogene cDNAs encode two proteins of 93.5 and 95 kDa resulting from alternative splicing. | None |
| Chromosomal assignment of two human B-raf(Rmil) proto-oncogene loci: B-raf-1 encoding the p94Braf/Rmil and B-raf-2, a processed pseudogene. | None |
| The authors have developed and run a high-throughput screen to find inhibitors of V600E BRAF using an enzyme cascade assay in which oncogenic BRAF activates MEK1, which in turn activates ERK2, which then phosphorylates the transcription factor ELK1. | None |
| Identification of inhibitors of the kinase activity of oncogenic V600E BRAF in an enzyme cascade high-throughput screen. | None |
| Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein. | None |
| Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. | None |
| A genome-wide RNA-interference screening to identify genes required for an activated BRAF oncogene to block proliferation of fibroblasts and melanocytes revealed that a IGFBP7, has a central role in BRAF-mediated senescence and apoptosis. | None |
| Oncogenic potential of BRAF versus RAS. | None |
| oncogenic BRAF inhibition can have a different effect on cell fate depending on the cellular type | None |
| oncogenic BRAF(V600E) induces the uncoupling of LKB1-AMPKalpha complexes providing at the same time a possible mechanism in cell proliferation that engages cell growth and cell division in response to mitogenic stimuli | None |
| Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. | None |
| Studies identified the oncogenic BRAF V600E mutation in 35 of 61 archived specimens (57%). | None |
| Development of a highly efficient expression cDNA cloning system: application to oncogene isolation. | None |
| The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. | None |
| the oncogenic effect of BRAF(V600E) is associated with the inhibition of MST1 tumor suppressor pathways, and the activity of RASSF1A-MST1-FoxO3 pathways determines the phenotypes of BRAF(V600E) tumors. | None |
| This study demonistrated that the role of RAF kinase fusions as a central oncogenic mechanism in the development of pilocytic astrocytoma. | None |
| This study defines a novel JAK3 mutation among patients with N-DS AML and demonstrates that normal individuals can also display germline JAK3 substitutions, previously proven to have oncogenic properties, in vitro and in vivo. | None |